» Articles » PMID: 38854123

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S Mutant Breast Cancer Cells

Overview
Journal bioRxiv
Date 2024 Jun 10
PMID 38854123
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations to estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective estrogen receptor modulators and degraders/downregulators (SERMs and SERDs) show clinical efficacy, but responses are often non-durable. A tyrosine to serine point mutation at position 537 in the ERα ligand binding domain (LBD) is among the most common and most pathogenic alteration in this setting. It enables endocrine therapy resistance by superceding intrinsic structural-energetic gatekeepers of ER hormone-dependence, it enhances metastatic burden by enabling neomorphic ER-dependent transcriptional programs, and it resists SERM and SERD inhibiton by reducing their binding affinities and abilities to antagonize transcriptional coregulator binding. However, a subset of SERMs and SERDs can achieve efficacy by adopting poses that force the mutation to engage in a new interaction that favors the therapeutic receptor antagonist conformation. We previously described a chemically unconventional SERM, T6I-29, that demonstrates significant anti-proliferative activities in Y537S ERα breast cancer cells. Here, we use a comprehensive suite of structural-biochemical, , and approaches to better T6I-29's activities in breast cancer cells harboring Y537S ERα. RNA sequencing in cells treated with T6I-29 reveals a neomorphic downregulation of , a secreted glycoprotein known to play oncogenic roles in other cancers. Importantly, we find that DKK1 is significantly enriched in ER+ breast cancer plasma compared to healthy controls. This study shows how new SERMs and SERDs can identify new therapeutic pathways in endocrine-resistant ER+ breast cancers.

References
1.
Fisher B, Costantino J, Redmond C, Fisher E, Wickerham D, Cronin W . Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86(7):527-37. DOI: 10.1093/jnci/86.7.527. View

2.
Giaquinto A, Sung H, Miller K, Kramer J, Newman L, Minihan A . Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022; 72(6):524-541. DOI: 10.3322/caac.21754. View

3.
Wardell S, Yllanes A, Chao C, Bae Y, Andreano K, Desautels T . Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. Breast Cancer Res Treat. 2019; 179(1):67-77. PMC: 6985185. DOI: 10.1007/s10549-019-05454-y. View

4.
Raj G, Sareddy G, Ma S, Lee T, Viswanadhapalli S, Li R . Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers. Elife. 2017; 6. PMC: 5548489. DOI: 10.7554/eLife.26857. View

5.
Michaud-Agrawal N, Denning E, Woolf T, Beckstein O . MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. J Comput Chem. 2011; 32(10):2319-27. PMC: 3144279. DOI: 10.1002/jcc.21787. View